Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetracyclic triterpenoid compound and its use in medicines

A compound and drug technology, applied in the field of new medicine research, can solve the problem of no compound anticancer activity found

Inactive Publication Date: 2016-10-05
BEIJING TUOLIN MEDICINE SCI & TECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After searching, no articles, patents or reports related to compound Y1218 and its anticancer activity have been found at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetracyclic triterpenoid compound and its use in medicines
  • Tetracyclic triterpenoid compound and its use in medicines
  • Tetracyclic triterpenoid compound and its use in medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Preparation of Y1218.

[0017] Routinely pulverize 60 kg of the dried Panax notoginseng crude drug, extract with ethanol, and extract 5 times with 1 liter of ethanol each time, and combine. Evaporate under reduced pressure to constant weight. 2.17 kg of ethanol extract was obtained. The ethanol extract was dissolved in hot water, and sequentially partitioned and extracted with n-hexane, ethyl acetate and n-butanol. Obtained n-butanol extract 0.73kg. The n-butanol extract was repeatedly separated by silica gel H (10-40 μm) column chromatography, and eluted with n-butanol: acetic acid: water = (2-8): (1-4): (3-7) gradient , get Fr1. Fr1 was repeatedly subjected to silica gel column chromatography and eluted with chloroform:methanol=(2-20):1 to obtain 0.78 g (0.013 parts per ten thousand) of Y1218.

Embodiment 2

[0019] Structural identification of Y1218.

[0020] Y1218 is white yellow powder. mp166-167; IR (cm -1 )3400, 2971, 1450, 1386; [α] 20 D +3.83°(MeOH; C=0.5); FAB-MS(m / z), 623[M+H] + , the main fragment peak 495[623-128(C 8 h 16 O, sidechain)] + , 461 [623-162 (Glc)] + , suggesting that there is a 6-carbon sugar, so it is speculated that its molecular weight is 622, and its molecular formula is C 36 h 62 o 8 ;Y1218 13 C NMR spectrum data compared with ginsenoside Rh2 except C 20 -C 27 Except for the difference, other data are basically the same. It shows that the basic skeleton of Y1218 is the same as that of Rh2, that is, the basic structure of dammarane type. 1 H MNR appears δ4.96 (1H, d, J=7.84Hz), indicating that the Y1218 molecule contains a β-configured pyranose, and Y1218 is hydrolyzed with hydrochloric acid to obtain D-glucopyranose, confirming that the sugar group is glucopyranose sugar. It is further confirmed that Y1218 and Rh2 except C 20 ~C 27 Exc...

Embodiment 3

[0025] Example 3 In vitro activity of Y1218 on tumor cells

[0026] Inhibitory effect on tumor cells in vitro Experimental tumor cells: metastatic colon cancer SW620, gastric adenocarcinoma BGC-823, etc. The in vitro cytotoxicity was measured by the MTT method, and 200ul of well-grown cells were taken and added to a 96-well plate, CO 2Incubate for 24 hours in the incubator. Add 20 μl / well of the test drug and incubate for 48 hours. Add 20 μl MTT into a 96-well plate, react for 4 hours, absorb the supernatant, add 20 μl DMSO / well, measure the absorbance value of each well at a wavelength of 570 nm with an enzyme-linked immunosorbent detector, and calculate the killing effect on cells. Determination of the concentration of Y1218 inhibiting 50% tumor cell growth (IC 50 ), and compared the strength of the effect with paclitaxel. The comparison results are shown in Table 1.

[0027] Table 1.Y1218 in vitro activity (IC 50 : μl / ml)

[0028] compound SW620 BGC-823 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The inventor researches Panax pseudoginseng Wall. var. notoginseng (Burkill) Hoo et Tseng antitumor activity, separates a tetracyclic triterpenoid monomer compound (with a code name of Y1218) from an active part of saponin and identifies a molecular structure of the tetracyclic triterpenoid monomer compound through modern spectroscopy. The tetracyclic triterpenoid monomer compound has antitumor effects.

Description

Technical field: [0001] The invention belongs to the field of new medicine research. The present invention relates to a compound with anti-cancer effect, specifically relates to its extraction and separation method and anti-cancer effect in vitro, and specifically relates to its preparation and application after compounding with a drug carrier (according to a certain proportion). technical background: [0002] Panax pseudoginseng (Latin name: Panax pseudoginseng Wall.var.notoginseng (Burkill) Hoo et Tseng) is a perennial herbaceous plant of the Araliaceae genus Panax, and it is also the branch and leaf part of the famous and precious Chinese medicine Panax notoginseng. Panax notoginseng has the effects of stopping bleeding and dissipating blood stasis, reducing swelling and relieving pain, etc. In recent years, it has been found that it has certain anti-tumor effects <Reference 1. Shang Xiliang, Fu Huaqun, Liu Jia, etc. Inhibitory effect of Panax notoginseng saponins on l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07J17/00A61K31/704A61P35/00A61P35/04
Inventor 刘桂珍董晓林张秀国杨明
Owner BEIJING TUOLIN MEDICINE SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com